Cryptococcosis in Dogs: Symptoms, Diagnosis, Treatment, and Species Guide
This article is reviewed for clinical accuracy. Always consult your veterinarian for diagnosis and treatment.
Key Takeaways
- Cryptococcosis in dogs is caused by two primary species: Cryptococcus neoformans (comprising varieties grubii and neoformans, the latter less common) and Cryptococcus gattii; unlike blastomycosis, histoplasmosis, and valley fever, which are thermally dimorphic fungi with mold and yeast forms, Cryptococcus is an encapsulated basidiomycetous yeast that exists in the yeast form both in the environment and in host tissue; the defining virulence feature is the massive polysaccharide capsule surrounding each yeast cell, which can be several times larger than the yeast cell itself; this capsule is the primary mechanism of immune evasion: it inhibits phagocytosis by macrophages and neutrophils, inhibits complement activation and opsonization, impairs T-cell stimulation, and actively suppresses cytokine production; the result is that Cryptococcus can survive and replicate in immunologically privileged sites (the CNS, the vitreous humor of the eye) where the immune response is inherently limited, and this accounts for the strong CNS tropism that distinguishes cryptococcosis from the other major fungal diseases of dogs.
- C. neoformans var. grubii (serotype A) is the most globally common variety and is strongly associated with aged pigeon (Columba livia) guano: pigeon droppings provide a nitrogen-rich alkaline substrate in which Cryptococcus replicates to enormous concentrations; roosting sites on building ledges, window sills, bridge supports, warehouse roofs, and urban structures accumulate guano over years; dried pigeon guano generates fine dust particles that remain airborne when disturbed and can carry Cryptococcus basidiospores and desiccated yeast cells that are small enough (1 to 2 micrometers when desiccated) to reach the terminal airways; C. neoformans causes disease primarily in immunosuppressed animals and humans (though immunocompetent dogs can be affected); in contrast, C. gattii is associated with eucalyptus trees in Australia and with Douglas fir, Western red cedar, and other conifers in the Pacific Northwest (British Columbia, Vancouver Island, Oregon, Washington State), and it causes disease in immunocompetent hosts without any underlying immunosuppression, often producing more invasive and treatment-resistant CNS disease than C. neoformans.
- Unlike blastomycosis (primarily respiratory in dogs), histoplasmosis (primarily GI in dogs), and valley fever (respiratory with bone dissemination), cryptococcosis in dogs most commonly presents with neurological signs as the primary or dominant complaint: meningoencephalitis from Cryptococcus produces a progressive neurological syndrome that may include seizures, behavioral changes, altered mentation, ataxia, circling, head tilt, cranial nerve deficits (particularly cranial nerves V, VII, and VIII), blindness from optic nerve involvement, and progressive obtundation leading to stupor and coma in advanced disease; many dogs with cryptococcal meningoencephalitis lack obvious upper respiratory signs at the time of presentation, so the owner history focuses on neurological deterioration without prior cough or respiratory illness; this contrasts with the other dimorphic fungi, where respiratory illness typically precedes neurological involvement.
- The most sensitive and practical diagnostic test for cryptococcosis in dogs is the cryptococcal antigen lateral flow assay (CrAg LFA), a point-of-care immunochromatographic strip test that detects the Cryptococcus polysaccharide capsular antigen in serum, plasma, urine, or CSF with sensitivity approaching 97 to 100 percent in dogs with active cryptococcal infection; the CrAg LFA (Immuno-Mycologics IMMY CrAg LFA) provides a semiquantitative titer result and can be run in-clinic in approximately 10 minutes; a positive CrAg in serum or CSF in a dog with compatible clinical signs (especially neurological signs) is a near-definitive diagnosis; the titer magnitude loosely correlates with the fungal burden and is used to monitor treatment response; India ink preparation of CSF, which demonstrates the characteristic large clear halo (the polysaccharide capsule) surrounding yeast cells, is pathognomonic when positive but has much lower sensitivity (approximately 25 to 50 percent) than the CrAg LFA.
- Treatment of CNS cryptococcosis in dogs requires a two-phase approach modeled on human immunocompromised patient protocols: an induction phase using amphotericin B (lipid formulation, 1 to 2 mg/kg IV three times weekly for 4 to 6 weeks) combined with flucytosine (25 to 50 mg/kg orally four times daily) to achieve rapid fungicidal activity and reduce the CNS fungal burden before transitioning to an oral consolidation phase; the consolidation and maintenance phase uses fluconazole (10 mg/kg twice daily is recommended for CNS disease) for a minimum of 6 to 12 months; for dogs with non-CNS cryptococcosis (nasal, cutaneous, isolated pulmonary), fluconazole alone (5 to 10 mg/kg once or twice daily) is generally sufficient; the massive polysaccharide capsule and the privileged CNS environment make Cryptococcus more difficult to eradicate than the other dimorphic fungi, contributing to the longer treatment durations and the need for combination induction therapy for CNS disease.
- The prognosis for canine cryptococcosis varies substantially by disease location and severity at diagnosis: dogs with nasal or cutaneous cryptococcosis without CNS involvement and a CrAg titer below 1:1,000 treated with fluconazole have a good prognosis, with survival rates above 70 to 80 percent in most reported series; dogs with CNS cryptococcosis have a more guarded prognosis, with approximately 40 to 60 percent survival in published veterinary series, reflecting both the inherent difficulty of treating a CNS fungal infection and the frequency with which CNS disease is diagnosed late after significant neurological injury has already occurred; dogs with C. gattii infection (in the Pacific Northwest) tend to have larger CNS lesions (cryptococcomas), higher initial CrAg titers, and more treatment-resistant disease than those with C. neoformans.
The 7-year-old Cocker Spaniel had been evaluated twice in the past six weeks for progressive behavioral changes: she was disoriented, circling to the left, and had stopped recognizing her owner. An MRI of the brain performed at a referral center showed multifocal ring-enhancing lesions in the forebrain and brainstem, and the radiology report listed “granulomatous meningoencephalitis (GME), neoplasia, and infectious encephalitis” as differentials. The neurology team drew CSF: the analysis showed markedly elevated protein (180 mg/dL) and a mixed pleocytosis. Microscopic examination of the CSF sediment under India ink showed several large round yeast cells surrounded by a dramatic clear halo several times the width of the yeast cell itself. A CrAg lateral flow assay strip run on a serum sample drew a strongly positive second line within 5 minutes. The CrAg titer was 1:2,048. The owner was asked about the dog’s environment: the family lived in an urban apartment building where pigeons roosted on the rooftop and ledges adjacent to the apartment windows. Amphotericin B plus flucytosine was started the same evening, followed at 6 weeks by long-term fluconazole. At the 3-month recheck, the CrAg titer had fallen to 1:128 and the dog had regained her ability to recognize her owner.
The Organism: Encapsulated Yeast with CNS Tropism
| Feature | C. neoformans var. grubii (Serotype A) | C. gattii (Serotypes B/C) |
|---|---|---|
| Primary environmental reservoir | Aged pigeon guano; also found in soil, decaying wood, and other bird droppings; worldwide distribution | Eucalyptus trees (Australia, California); Douglas fir, Western red cedar, and other conifers in the Pacific Northwest (British Columbia, Oregon, Washington State, Idaho) |
| Host immune status | Predominantly immunosuppressed hosts in clinical disease; immunocompetent dogs can be affected but face lower risk per exposure | Immunocompetent hosts; C. gattii causes disease without any identifiable underlying immunosuppression; this is a key distinguishing feature |
| Geographic distribution | Worldwide; wherever pigeons are present; highest clinical burden in urban areas with dense pigeon populations | Originally described in Australia and tropical regions; Pacific Northwest outbreak since approximately 1999 (Vancouver Island) spreading into Oregon and Washington; California (southern and central coastal regions) |
| CNS lesion character | Diffuse meningoencephalitis; leptomeningeal enhancement on MRI; large gelatinous accumulations of capsular polysaccharide (gelatinous pseudocysts) in Virchow-Robin spaces | Larger discrete granulomatous lesions (cryptococcomas); mass-like ring-enhancing lesions on MRI that closely mimic brain tumors; higher capsular antigen titers; more aggressive CNS disease |
| Treatment response | Generally more responsive to standard fluconazole and amphotericin B protocols | More treatment-resistant; may require longer induction, higher doses, or addition of flucytosine throughout the treatment course |
| Virulence factors | Polysaccharide capsule; laccase (melanin production, free radical scavenging); phospholipase B; urease; ability to grow at 37 degrees Celsius | Same virulence factors; capsule may be larger and more immunosuppressive; some strains have enhanced phospholipase activity |
Comparison: Cryptococcosis vs. Other Fungal Diseases in Dogs
| Feature | Cryptococcosis | Blastomycosis | Histoplasmosis | Valley Fever |
|---|---|---|---|---|
| Dominant presentation | Neurological (meningoencephalitis); nasal/upper respiratory | Respiratory (pulmonary nodules); skin; eyes; bone | GI (diarrhea, PLE); liver; spleen | Respiratory; bone (mimics osteosarcoma) |
| Geographic distribution | Nationwide (wherever pigeons present); C. gattii in Pacific Northwest | Mississippi/Ohio River valleys; Great Lakes | Mississippi/Ohio River valleys; mid-Atlantic | Southwestern US desert (AZ, CA, NM, TX, NV) |
| Best rapid diagnostic test | CrAg LFA serum or CSF (sensitivity near 100%) | FNA cytology or urine antigen EIA | Rectal scraping cytology or urine antigen EIA | AGID serology and CF titer |
| Preferred first-line treatment | Fluconazole (CNS: amphotericin B + flucytosine induction) | Itraconazole | Itraconazole | Fluconazole |
| Treatment duration | 6 to 12 months minimum; CNS often longer | 2 to 3 months minimum | 4 to 6 months minimum | 6 to 24 months; sometimes lifelong |
| Organism morphology on cytology | Large encapsulated yeast (4 to 20 micrometers) with narrow-base budding; huge clear capsular halo on India ink | Large (8 to 15 micrometers) extracellular yeast with broad-base budding; thick double-contoured wall | Small (2 to 4 micrometers) intracellular yeast within macrophages | Very large spherules (60 to 200 micrometers) packed with endospores |
Clinical Signs by System
| System | Clinical Signs | Frequency |
|---|---|---|
| CNS/Neurological (most common) | Seizures (focal or generalized); behavioral changes (aggression, disorientation, loss of learned behaviors); circling; head tilt; vestibular ataxia; cranial nerve deficits (facial drooping, altered jaw tone, deafness, nystagmus); progressive obtundation; neck pain from meningitis; blindness from optic nerve or intracranial involvement | 40 to 60 percent of dogs with cryptococcosis; the most common reason for referral to neurology in dogs with this disease |
| Nasal/Sinonasal | Chronic unilateral or bilateral nasal discharge (serous to mucopurulent); sneezing; epistaxis; nasal mass visible on rhinoscopy; facial deformity (bridge of nose swelling, soft tissue mass over nasal bones from granuloma eroding through bone and skin); submandibular lymphadenopathy | 30 to 50 percent of cases; nasal cryptococcosis without CNS involvement has a better prognosis than CNS disease |
| Ocular | Chorioretinitis (focal white retinal lesions); optic neuritis (acute blindness, absent pupillary light reflex, pale optic disc); uveitis (aqueous flare, hypopyon, corneal edema); retinal detachment; secondary glaucoma | 20 to 40 percent of cases; ocular cryptococcosis may be the first recognized sign; optic nerve involvement can cause acute bilateral blindness |
| Cutaneous | Firm subcutaneous nodules, particularly on the face, bridge of nose, lips, and gingiva; ulcerated papules; draining granulomas on the head and neck; skin lesions are more common with C. neoformans than C. gattii | 15 to 25 percent of cases |
| Respiratory/Pulmonary | Cough; exercise intolerance; thoracic radiographs showing focal or diffuse interstitial infiltrate; hilar lymphadenopathy; pleural effusion in severe cases; less commonly presents as primary respiratory disease in dogs than in cats or humans | 20 to 35 percent of cases; pulmonary disease often subclinical while CNS or nasal disease dominates the presentation |
| Constitutional | Weight loss; fever (may be absent in dogs with CNS disease); lethargy; inappetence | Variable; systemic signs are less prominent in nasal/cutaneous disease |
Diagnosis
Cryptococcal Antigen Lateral Flow Assay (CrAg LFA)
The CrAg LFA (IMMY CrAg LFA; Immuno-Mycologics) is the most sensitive and practical diagnostic test for cryptococcosis and can be run in-clinic on serum, plasma, urine, or CSF in approximately 10 minutes; the test detects capsular polysaccharide glucuronoxylomannan (GXM) shed by actively replicating Cryptococcus yeast; sensitivity approaches 97 to 100 percent in dogs with active systemic or CNS cryptococcal infection; results are read as positive/negative with a semiquantitative titer; a positive CrAg in a dog with compatible neurological or upper respiratory signs effectively confirms cryptococcosis and should prompt immediate initiation of antifungal therapy; the CrAg is also used for treatment monitoring: serial titers declining by two or more dilution steps over the treatment course indicate therapeutic response; a stable or rising CrAg titer during treatment indicates treatment failure; the CrAg can remain weakly positive for months after clinical cure (residual antigen after organism clearance), so treatment decisions at the end of a treatment course must integrate CrAg titer trend, clinical status, and CSF analysis rather than a single antigen result.
CSF Analysis
Cerebrospinal fluid analysis is essential for dogs with neurological signs; CSF from dogs with cryptococcal meningoencephalitis typically shows elevated protein (often markedly elevated above 50 mg/dL), a mixed pleocytosis (combination of neutrophils, monocytes, and macrophages), and occasionally direct visualization of Cryptococcus yeast on CSF cytology; India ink preparation of the CSF sediment, in which the polysaccharide capsule appears as a large clear halo surrounding the yeast cell body against the dark India ink background, is pathognomonic when positive (sensitivity approximately 25 to 50 percent in dogs); the CrAg LFA should be performed on the CSF specimen in addition to serum in dogs with suspected CNS cryptococcosis, as CSF CrAg titers may be higher than serum titers in dogs with severe CNS disease; MRI of the brain shows leptomeningeal enhancement, multifocal ring-enhancing lesions (particularly with C. gattii), hydrocephalus from obstructed CSF flow, and dilated Virchow-Robin spaces filled with gelatinous polysaccharide material.
Cytology from Accessible Lesions
Nasal discharge cytology, fine-needle aspirate of nasal masses or subcutaneous nodules, and aspirate of draining skin lesions frequently yield Cryptococcus yeast directly; on Diff-Quik or Wright-Giemsa stained smears, the yeast appear as round to oval cells (4 to 20 micrometers) with a faint but visible halo representing the polysaccharide capsule and narrow-base budding (distinguishing them from Blastomyces, which has broad-base budding); the capsule may appear as a clear unstained zone around each yeast cell on routine stains; mucicarmine staining specifically highlights the polysaccharide capsule bright red, which is used in histopathology to confirm Cryptococcus identity.
Rhinoscopy and CT of Nasal Passages
Dogs with nasal cryptococcosis benefit from CT imaging of the nasal passages and sinuses, which demonstrates soft tissue mass lesions within the nasal cavity, turbinate destruction, sinus involvement, and cribriform plate erosion (the bony plate separating the nasal cavity from the cranial vault); cribriform plate erosion indicates that nasal disease may have direct intracranial extension and is associated with a worse prognosis; rhinoscopy allows direct visualization and biopsy of intranasal masses and collection of material for cytology, culture, and sensitivity testing.
Treatment
Non-CNS Cryptococcosis (Nasal, Cutaneous, Pulmonary)
Fluconazole at 5 to 10 mg/kg orally once or twice daily is the treatment of choice for dogs with nasal, cutaneous, or pulmonary cryptococcosis without CNS involvement; treatment duration is a minimum of 6 months and continues until the CrAg titer has declined significantly (ideally to negative or the lowest achievable level) and remained stable; itraconazole at 5 mg/kg orally once daily is an alternative; dogs with nasal cryptococcosis have a good prognosis (survival rates above 70 percent) when CNS involvement has been excluded by brain MRI and CSF analysis before starting treatment; nasal disease that does not respond to fluconazole should prompt reevaluation for cribriform plate erosion and occult CNS extension.
CNS Cryptococcosis: Induction Phase
CNS cryptococcosis requires a two-phase treatment protocol because the CNS environment is immunologically privileged (low antibody concentrations, limited phagocyte access, reduced complement activity) and the large polysaccharide capsule allows Cryptococcus to persist at fungistatic azole concentrations; the induction phase uses fungicidal combination therapy to rapidly reduce the CNS fungal burden:
- Amphotericin B lipid formulation (AmBisome or Abelcet): 1 to 2 mg/kg IV three times weekly for 4 to 6 weeks; renal function monitoring before each infusion; conventional amphotericin B deoxycholate can be used if lipid formulation is unavailable but has substantially higher nephrotoxicity
- Flucytosine (5-FC): 25 to 50 mg/kg orally four times daily throughout the induction phase; flucytosine is a pyrimidine antifungal that is taken up by fungal cells (via cytosine permease that mammalian cells lack) and converted to 5-fluorouracil, which inhibits fungal DNA and RNA synthesis; it has excellent CNS penetration; flucytosine must not be used as monotherapy because resistance develops rapidly; CBC monitoring during flucytosine treatment is required because bone marrow suppression (leukopenia, thrombocytopenia) can occur, particularly when serum flucytosine concentrations are elevated (renal insufficiency impairs flucytosine clearance)
CNS Cryptococcosis: Consolidation and Maintenance Phase
After completing the amphotericin B induction phase (minimum 4 to 6 weeks, or until the dog shows neurological improvement and the CrAg titer begins declining), treatment transitions to oral fluconazole at 10 mg/kg twice daily for a minimum of 6 to 12 months; the total treatment duration is guided by clinical response, neurological examination, serial CrAg titers, and repeat MRI at 3 to 6-month intervals; dogs with C. gattii infection, cryptococcomas, or persistently elevated CrAg titers may require 18 to 24 months of consolidation or indefinite suppressive therapy; dose reduction below 10 mg/kg twice daily during consolidation is a common cause of relapse and should not be done based on clinical improvement alone without concurrent CrAg titer decline.
Increased Intracranial Pressure
The massive polysaccharide capsule shed by replicating Cryptococcus accumulates in the subarachnoid space and Virchow-Robin spaces, creating gelatinous pseudocysts that can obstruct CSF flow and raise intracranial pressure; signs of elevated intracranial pressure (papilledema on fundoscopy, obtundation, Cushing’s reflex of hypertension and bradycardia, worsening neurological signs despite antifungal therapy) require medical management with mannitol (0.5 to 1.0 g/kg IV bolus) to reduce intracranial pressure acutely; serial therapeutic CSF drainage (lumbar or cisterna magna puncture) to reduce CSF pressure is performed in human cryptococcal meningitis patients and is increasingly applied in veterinary patients with refractory intracranial hypertension.
US Cost Overview for Cryptococcosis
| Service | Typical US Cost |
|---|---|
| Veterinary examination | $60 to $150 |
| CrAg LFA (serum, point of care) | $30 to $70 |
| CrAg titer (quantitative, reference lab) | $60 to $120 |
| Complete blood count and chemistry panel | $150 to $300 |
| Brain MRI | $1,500 to $3,500 |
| CSF collection, analysis, and India ink prep | $300 to $700 |
| CT of nasal passages | $500 to $1,200 |
| Rhinoscopy with biopsy | $600 to $1,400 |
| Fluconazole (12-month course, 20 kg dog at 10 mg/kg BID) | $200 to $600 |
| Amphotericin B lipid formulation (per infusion) | $200 to $500 per infusion plus hospitalization |
| Flucytosine (4 to 6 weeks, 20 kg dog) | $300 to $700 |
| Monthly CBC during flucytosine therapy | $80 to $150 |
| Serial CrAg titer monitoring (every 2 to 3 months) | $60 to $120 per titer |
| Repeat brain MRI (every 6 months during treatment) | $1,500 to $3,500 |
Age-Specific Considerations
Puppies (Under 12 Months)
- Puppies with cryptococcosis are relatively uncommon because the disease requires either a substantial environmental inoculum or some degree of immunological susceptibility; however, puppies from environments with dense pigeon populations (urban apartments where pigeons roost on adjacent structures) can develop primary nasal or pulmonary cryptococcosis; the immature immune system may allow more rapid dissemination from nasal to CNS in puppies than in adult dogs; any puppy from an urban environment with pigeon exposure that develops chronic nasal discharge, sneezing, or neurological signs should have a CrAg lateral flow assay performed as part of the workup
- Flucytosine dosing in puppies requires careful attention to bone marrow effects because puppies have higher bone marrow activity (active hematopoiesis to support growth) and may be more sensitive to 5-FC bone marrow suppression; weekly CBC monitoring during the induction phase is appropriate in puppies; if neutropenia or thrombocytopenia develops, the flucytosine dose should be reduced or discontinued with substitution of fluconazole at a higher dose for the induction phase; renal function influences flucytosine clearance, so baseline and periodic creatinine measurement during 5-FC therapy is warranted
- Amphotericin B nephrotoxicity is a significant concern in puppies because their glomerular filtration rate per unit body weight is different from adults and may not yet be at full adult capacity; lipid-formulation amphotericin B (AmBisome, Abelcet) is strongly preferred over conventional amphotericin B deoxycholate for puppies requiring induction therapy because the lipid formulation delivers dramatically less nephrotoxic free amphotericin B to the kidney; generous IV fluid support before, during, and after AMB infusions reduces nephrotoxic risk in all patients including puppies
Adult Dogs (1 to 8 Years)
- Adult dogs in the 3 to 7-year age range are the most commonly affected group in cryptococcosis case series; large breeds (Great Danes, Labrador Retrievers, American Cocker Spaniels, and Doberman Pinschers) appear to be overrepresented in some studies, possibly reflecting breed-associated immune differences or behavioral differences in environmental exposure; dogs living in urban apartments with pigeon-infested buildings, or dogs in rural areas of British Columbia, Oregon, or Washington State in proximity to conifer forests, carry the highest exposure risks for C. neoformans and C. gattii, respectively
- The most important diagnostic challenge for adult dogs with cryptococcal meningoencephalitis is the radiographic and CSF pattern overlap with granulomatous meningoencephalitis (GME), neoplasia, and other infectious encephalitides; an adult dog with multifocal ring-enhancing brain lesions and mixed CSF pleocytosis on MRI represents a genuine diagnostic challenge where cryptococcal meningoencephalitis, brain metastases, and GME all remain on the differential; the CrAg LFA is the cheapest and fastest test that can exclude cryptococcosis from that differential and should be the first test performed (before trying empirical anti-inflammatory therapy) in any dog with multifocal brain lesions from an endemic area or known pigeon exposure
- Adult dogs with nasal cryptococcosis often have a prolonged history of chronic nasal discharge that has been treated with multiple antibiotic courses without lasting improvement; any adult dog with a chronic unilateral nasal discharge that has failed to resolve with appropriate antibiotic therapy and is from an area with pigeon populations should have a CrAg LFA, nasal CT, and rhinoscopy before further antibiotic therapy is prescribed; chronic unilateral nasal discharge in adult dogs that is not caused by dental disease (tooth root abscess) has a broad differential including cryptococcosis, aspergillosis, neoplasia, and nasal foreign body; each of these requires a specific diagnosis rather than empirical antibiotic treatment
Senior Dogs (9 Years and Older)
- Senior dogs are at higher risk for cryptococcosis-associated CNS disease relative to younger dogs for two reasons: age-related immunosenescence reduces the efficiency of cell-mediated immune responses that normally prevent Cryptococcus CNS dissemination, and senior dogs are more likely to be receiving immunosuppressive medications (corticosteroids for arthritis, allergies, or immune-mediated disease; chemotherapy for lymphoma or other neoplasia) that further impair T-lymphocyte-mediated fungal containment; any senior dog on chronic corticosteroids from an urban environment with pigeon exposure who develops new neurological signs should have a CrAg LFA as one of the first diagnostic steps, before escalating the steroid dose or adding other immunosuppressants
- Senior dogs with concurrent renal insufficiency (chronic kidney disease stage 2 or above, serum creatinine consistently above 1.4 mg/dL) present a treatment challenge for cryptococcal CNS disease: amphotericin B is nephrotoxic, and flucytosine is renally cleared; lipid-formulation AMB at the lowest effective dose with aggressive IV fluid support reduces nephrotoxic risk but does not eliminate it; flucytosine dose reduction based on GFR calculation (creatinine clearance) is necessary to prevent accumulation and bone marrow toxicity; in senior dogs with advanced CKD where AMB induction carries prohibitive nephrotoxic risk, high-dose fluconazole (10 to 15 mg/kg twice daily) alone as induction therapy with close monitoring is a compromise, though CNS outcomes are generally worse with azole-only induction for severe CNS disease
- Cryptococcal CNS disease in senior dogs is frequently misattributed to primary brain aging changes, cognitive dysfunction syndrome (CDS), vestibular disease (particularly “old dog vestibular disease”), or brain tumor; these are all legitimate considerations in senior dogs with neurological signs, but none of them would produce a positive CrAg LFA; a simple serum CrAg test can exclude cryptococcosis immediately and costs less than 10 percent of the price of a brain MRI; testing for cryptococcosis before committing to costly neurological workup or empirical steroid therapy is cost-effective and clinically important in senior dogs from endemic areas
Myths and Facts About Cryptococcosis in Dogs
Cryptococcosis is a disease of cats, not dogs, so my dog’s neurological signs can’t be from Cryptococcus.
While cats are more commonly diagnosed with cryptococcosis than dogs (cats have a higher prevalence of natural exposure and possibly some species-specific susceptibility differences), dogs develop clinically significant cryptococcosis at meaningful rates across all geographic areas where pigeons are present, which is essentially nationwide. Canine cryptococcosis case series have been published from across the US, Australia, and Europe. Dogs in urban environments with pigeon exposure face genuine exposure risk. The CrAg LFA is a rapid, inexpensive, highly sensitive test that excludes cryptococcosis in minutes and should not be skipped based on a species-association assumption.
My dog tested positive on the CrAg but feels fine right now, so we should wait and monitor before starting treatment.
A positive CrAg in a dog with any neurological signs, nasal signs, or ocular signs compatible with cryptococcosis indicates active fungal infection that warrants immediate treatment, not watchful waiting. Cryptococcal CNS disease is progressive and can cause irreversible neurological injury if treatment is delayed; the window for preventing permanent deficits is narrow. For a completely asymptomatic dog with a weakly positive CrAg and no suggestive clinical signs, a veterinary consultation to assess whether the titer represents subclinical infection or cross-reactivity is appropriate, but any dog with symptoms should begin antifungal therapy promptly.
My dog had cryptococcosis and finished the fluconazole; once the prescription is gone, treatment is done and no follow-up is needed.
Cryptococcosis, particularly CNS disease, has a relapse rate of 20 to 30 percent when treatment is stopped prematurely or monitoring is inadequate. The CrAg titer must show a sustained downward trend and approach low or undetectable levels before treatment is safely discontinued. For CNS disease, a repeat brain MRI confirming lesion resolution or significant improvement is also advisable before stopping therapy. Serial CrAg titers every 2 to 3 months for at least 6 months after stopping fluconazole provide early detection of relapse before it becomes clinically severe.
Red Flags: Signs Requiring Same-Day or Emergency Evaluation
- Acute-onset seizures in a dog with known or suspected cryptococcosis, or in any dog from an urban environment with pigeon exposure: cryptococcal meningoencephalitis is an immediately life-threatening cause of new-onset seizures in any age dog; emergency CrAg LFA from a serum sample can be performed in 10 minutes and should be part of the seizure workup in any dog from an urban area, particularly if the dog lives in a building with visible pigeon roosting; seizure management with diazepam or levetiracetam and emergency antifungal therapy (if cryptococcosis is confirmed or highly suspected) must proceed concurrently
- Acute bilateral blindness with absent pupillary light reflexes in a dog with other neurological signs: optic nerve cryptococcosis can cause acute irreversible bilateral blindness within hours to days of optic neuritis onset; a dog with acute blindness should receive an emergency ophthalmological examination to evaluate for retinal detachment, optic disc swelling, and uveitis, and a concurrent CrAg LFA; prompt antifungal therapy may preserve residual visual function but cannot restore vision lost to optic nerve infarction or retinal detachment
- Rapidly progressive neurological deterioration (increasing obtundation, worsening ataxia, new cranial nerve deficits over 24 to 48 hours) in a dog with diagnosed cryptococcal meningoencephalitis on fluconazole alone: progressive CNS deterioration during oral azole therapy indicates that the fungistatic activity of fluconazole is insufficient to contain CNS fungal replication; these dogs require urgent escalation to induction therapy with amphotericin B plus flucytosine, evaluation for elevated intracranial pressure, and immediate consultation with an internal medicine or neurology specialist
- Facial bone deformity, soft tissue swelling over the bridge of the nose, or a visibly enlarging nasal mass with concurrent behavioral changes in a dog: nasal cryptococcosis with cribriform plate erosion and direct intracranial extension is an emergency that requires CT of the nasal passages and skull base, brain MRI, and CSF analysis to determine the extent of CNS involvement; cribriform plate erosion changes the prognosis from good (nasal disease only) to guarded (CNS extension) and significantly alters the treatment protocol
- Signs of increased intracranial pressure (obtundation progressing to stupor, Cushing’s reflex of hypertension and bradycardia, rigidly extended limbs, loss of pupillary responses) in a dog with CNS cryptococcosis: elevated intracranial pressure from gelatinous pseudocysts and impaired CSF drainage requires emergency management with IV mannitol to reduce brain herniation risk; these dogs require intensive care-level monitoring and urgent involvement of a neurologist
Frequently Asked Questions About Cryptococcosis in Dogs
What is cryptococcosis in dogs?
Cryptococcosis is a systemic fungal infection caused by Cryptococcus neoformans (associated with pigeon guano, worldwide) and C. gattii (associated with conifers in the Pacific Northwest and eucalyptus in Australia). Unlike the dimorphic fungi (blastomycosis, histoplasmosis, valley fever), Cryptococcus is an encapsulated yeast whose massive polysaccharide capsule allows it to evade immune defenses and spread to the CNS. Dogs most commonly present with neurological signs from meningoencephalitis, nasal disease, or ocular involvement.
What are the symptoms of cryptococcosis in dogs?
Neurological signs (seizures, behavioral changes, ataxia, circling, cranial nerve deficits, blindness) are the most common presenting complaint because Cryptococcus has a strong predilection for the CNS. Nasal disease (chronic discharge, sneezing, nasal mass) and ocular signs (uveitis, blindness) are also common. Cutaneous nodules on the face and skin, respiratory signs, and systemic weight loss may occur. Many dogs lack prominent cough or respiratory signs even with pulmonary involvement.
How is cryptococcosis diagnosed in dogs?
The cryptococcal antigen lateral flow assay (CrAg LFA) on serum or CSF is the fastest and most sensitive diagnostic test, with sensitivity near 97 to 100 percent; it runs in approximately 10 minutes in-clinic. India ink preparation of CSF showing the characteristic large clear halo (polysaccharide capsule) surrounding yeast cells is pathognomonic when positive. Brain MRI, CSF analysis, and cytology of nasal discharge or skin lesions provide additional diagnostic and prognostic information.
What is the treatment for cryptococcosis in dogs?
For non-CNS disease (nasal, cutaneous), fluconazole 5 to 10 mg/kg once or twice daily for 6 months or longer is the standard treatment. For CNS disease, an induction phase of amphotericin B (lipid formulation) plus flucytosine for 4 to 6 weeks is followed by oral fluconazole at 10 mg/kg twice daily for at least 6 to 12 months. Serial CrAg titers every 2 to 3 months guide treatment duration. Elevated intracranial pressure may require mannitol or serial CSF drainage.
Where is cryptococcosis most common in dogs?
C. neoformans is worldwide wherever pigeons roost; urban dogs in apartment buildings, warehouses, and other structures with dense pigeon populations face the highest exposure risk. C. gattii is concentrated in the Pacific Northwest (British Columbia, Vancouver Island, Oregon, Washington State) and poses risk to dogs in forested areas of those regions. Unlike blastomycosis, histoplasmosis, and valley fever, cryptococcosis has no single US regional hot spot because pigeon populations are national.
Can my dog give me cryptococcosis?
Direct dog-to-human transmission of cryptococcosis is not documented. Both dogs and humans acquire cryptococcosis from the same environmental sources: pigeon guano or soil near conifer trees in the case of C. gattii. Handling an infected dog’s nasal discharge or skin lesions carries minimal theoretical risk, and standard hygiene (handwashing after handling an infected dog’s lesions) is sufficient precaution. Immunosuppressed humans should discuss additional precautions with their physician when caring for a dog with active cryptococcosis.
What is the prognosis for dogs with cryptococcosis?
Prognosis depends heavily on disease location: dogs with nasal or cutaneous cryptococcosis without CNS involvement treated with fluconazole have survival rates above 70 percent. CNS cryptococcosis carries a more guarded prognosis, with approximately 40 to 60 percent survival; C. gattii CNS disease in particular tends to be more aggressive and treatment-resistant. Early diagnosis (before severe neurological injury) and prompt initiation of appropriate therapy are the most important factors in improving outcomes.
For more guides on keeping your dog healthy, browse all our Dog Health articles.
Explore Dog Health Articles